ClinicalTrials.gg
CompletedNCT02411825Updated Jun 15, 2018

Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients

A Phase 1 interventional study of SAR425899 and placebo in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-15.

Sponsored by Sanofi · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
172nd of 287
76 · median 100
Started
2015
with 11 others
Phase 1
55 of 293
2 open now
Registered
198th of 293
by date
Lead sponsor
14 of 293
Sanofi

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 172nd largest by enrollment of the 287 interventional ones that give a count, is one of 12 that started in 2015, is one of 55 in phase 1, and was the 198th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To assess in healthy adult male subjects:

  • The tolerability and safety of 21-day repeated subcutaneous (SC) doses of SAR425899 including two up titration steps.
  • Pharmacokinetic (PK) parameters of SAR425899 after ascending repeated SC doses in plasma.
  • Pharmacodynamic (PD) effects on fasting and postprandial plasma glucose, insulin, biomarkers of lipid metabolism and fibroblast growth factor 21 (FGF21).

To assess in overweight to obese T2DM mellitus patients:

  • The tolerability and safety after 28-day repeated SC doses of SAR425899 including 2 up titration steps.
  • PK parameters of SAR425899 after ascending repeated SC doses in plasma and urine.
  • PD effects on fasting and postprandial plasma glucose, insulin, C-peptide, incretin panel (total and active ghrelin, total peptide YY [PYY], total and active glucagon-like peptide -1 [GLP-1], glucagon and total gastric inhibitory polypeptide-1 [GIP]), body weight, FGF21, biomarkers of lipid metabolism and HbA1c.
Read the detailed description

The total study duration is approximately 10-15 weeks.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy subjects:

  • Males, between 18 and 55 years of age, inclusive.
  • (BMI) between 20.0 and 30.0 kg/m\^2, inclusive; body weight between 50.0 and 120.0 kg, inclusive.
  • Certified as healthy by comprehensive clinical assessment (detailed medical history, complete physical examination). Comorbidities of higher weight (eg, mild impaired glucose tolerance, mild hypertension, mild hyperlipidemia) are permitted unless, per investigator, these conditions hamper participation.
  • Normal vital signs after 10 minutes resting supine:
  • 95 mmHg \<systolic blood pressure (SBP) \<150 mmHg.
  • 45 mmHg \<diastolic blood pressure (DBP) \<100 mmHg.
  • 50 bpm \<heart rate (HR) \<100 bpm.
  • Standard 12-lead (ECG) parameters after 10 minutes resting in supine position within; 120 ms \<PR \<220 ms, QRS \<120 ms, ≤430 ms, normal ECG.
  • Normal 24-hour Holter electrocardiography at screening.
  • Laboratory parameters within normal range; however serum creatinine, alkaline phosphatase, hepatic enzymes (, alanine aminotransferase), and total (unless subject has Gilbert syndrome) should not exceed upper laboratory norm ().

T2DM patients:

  • Males and females, 18-70 years of age.
  • Body weight 50.0-150.0 kg, BMI 28.0 - 42.0 kg/m\^2.
  • Diagnosis of T2DM for at least 1 year with stable metformin prior to inclusion; comorbidities related to T2DM but otherwise healthy.
  • Normal vital signs supine:
  • 95 mmHg \< SBP \<160 mmHg
  • 45 mmHg \< DBP \<100 mmHg
  • 50 bpm \< HR \<100 bpm
  • Normal standard 12-lead ECG in supine position unless abnormality is clinically irrelevant.
  • Laboratory parameters in normal range unless abnormality is clinically irrelevant or strongly associated with T2DM; total bilirubin not to exceed ULN.
  • Fasting plasma glucose ≥90 mg/dL.
  • ≥6.5% and ≤8.5%.
  • Females: Sterilization at least 3 months before inclusion or .

Both:

  • Signed written .
  • Not supervised/confined for legal or administrative reasons.
  • Male subject with partner of (including lactating women) must use double method.
  • Male subject with pregnant partner must use a condom up to 2 months after last dosing.
  • Male subject agreed not to donate sperm up to 2 months after last dosing.
  • Not undergoing physical training program/planning changes in activity; not vegetarian or following special diet.

Exclusion criteria

Exclusion criteria:

Healthy subjects:

  • History of disease/signs of acute illness.
  • History of drug /allergic disease.
  • Smoking more than 5 cigarettes/day.
  • Any medication within 14 days before inclusion or within 5 times elimination/pharmacodynamic half-life of the medication and during study; vaccination within last 28 days, biologics given within 4 months before inclusion.

T2DM patients:

  • History/presence of clinically relevant disease/signs of acute illness not related to patient's metabolic status.
  • History/presence of drug hypersensitivity or allergic disease.
  • Smoking more than 5 cigarettes per day.
  • If female, pregnancy/breast-feeding.
  • Any intake of medication during treatment period and within 21 days before first dosing or within 5 times half-life of the medication, except: metformin, standard antihypertensive treatment, statins, acetyl salicylic acid.
  • Thyroid hormone replacement is allowed if dose was stable for 3 months prior to screening.
  • Individual background therapy, considered necessary for the patient's welfare, that could not be discontinued for the duration of the study, may be given at the discretion of the Investigator, with a stable dose (when possible) and only if its intake is unlikely to interfere with the product.
  • Treated with sulphonyl-ureas up to 3 months, proton pump inhibitors up to 1 week prior to dosing.
  • Vaccination within last 28 days, any biologics within 4 months before inclusion.
  • Severe hypoglycemia resulting in seizure/unconsciousness/coma/hospitalization for diabetic ketoacidosis in last 3 months before screening.
  • Persistent hyperglycemia not controlled by metformin/diet/exercise.
  • Diabetic neuropathy, retinopathy, nephropathy or renal impairment.
  • Hepatic impairment.
  • Unstable hypo- or hyperthyroidism.

Both:

  • Headaches/migraine.
  • Recurrent nausea/vomiting.
  • Blood donation within 1 month before inclusion.
  • Symptomatic postural hypotension, irrespective of decrease in BP, or asymptomatic postural hypotension defined as decrease in SBP ≥20 mmHg within 3 minutes when changing from supine to standing.
  • History/presence of drug or alcohol abuse.
  • Positive result: surface antigen, anti- virus antibodies, anti- 1 and 2 antibodies.
  • Any condition affecting gastric emptying or absorption from GI tract.
  • Surgically treated obesity, bariatric surgery.
  • Severe dyslipidemia with fasting triglycerides >450 mg/dL.
  • History of pancreatitis or pancreatectomy.
  • Amylase/lipase >3 .
  • History of thyroid cancer or a genetic condition that predisposes to thyroid cancer.
  • Elevated basal calcitonin.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    SAR425899 (healthy subjects)

    Once daily SC doses of SAR425899

    Drug: SAR425899

  • Placebo comparator
    Placebo (healthy subjects)

    Once daily SC doses of placebo

    Drug: placebo

  • Experimental
    SAR425899 (T2DM Patients)

    Once daily SC doses of SAR425899 and two up titration steps in each dose cohort with metformin as background therapy

    Drug: SAR425899 · Drug: metformin

  • Placebo comparator
    Placebo (T2DM Patients)

    Once daily SC doses of placebo and two up titration steps in each dose cohort with metformin as background therapy

    Drug: placebo · Drug: metformin

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • Drugplacebo

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • Pharmaceutical form: tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Number of adverse events

    Time frame: 28 to 35 days

Secondary outcomes

  1. Changes in vital signs

    Time frame: 28 to 35 days

  2. Changes in physical examination

    Time frame: 28 to 35 days

  3. Changes in ECG

    Time frame: 28 to 35 days

  4. Changes in clinical laboratory parameters (hematology)

    Time frame: 28 to 35 days

  5. Changes in clinical laboratory parameters (biochemistry)

    Time frame: 28 to 35 days

  6. Changes in body temperature

    Time frame: 28 to 35 days

  7. Change from baseline in biomarkers (FGF21)

    Time frame: 28 to 35 days

  8. Change from baseline in biomarkers (lipid biomarker)

    Time frame: 28 to 35 days

  9. Change from baseline in biomarkers (incretins)

    Time frame: 28 to 35 days

  10. Assessment of pharmacokinetic parameters in blood (AUC)

    Time frame: 28 to 35 days

  11. Assessment of pharmacokinetic parameters in blood (Cmax)

    Time frame: 28 to 35 days

  12. Assessment of pharmacokinetic parameters in blood (t1/2)

    Time frame: 28 to 35 days

  13. Assessment of pharmacokinetic parameters in urine (Ae0-24)

    Time frame: 28 to 35 days

  14. Assessment of pharmacokinetic parameters in urine (fe0-24)

    Time frame: 28 to 35 days

  15. Change from baseline in Body weight

    Time frame: 28 to 35 days

  16. Change from baseline in Fasting Blood Glucose

    Time frame: 28 to 35 days

  17. Change from baseline in Postprandial Blood Glucose

    Time frame: 28 to 35 days

  18. Change from baseline in postprandial Insulin

    Time frame: 28 to 35 days

  19. Change from baseline in postprandial C-peptide profiles

    Time frame: 28 to 35 days

  20. Change from baseline in HbA1c

    Time frame: 28 to 35 days

07

Study locations

1 site
  • Investigational Site Number 276001
    Berlin, 10117, Germany
08

References and documents

Publications

  • Visentin R, Schiavon M, Gobel B, Riz M, Cobelli C, Klabunde T, Dalla Man C. Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes. Diabetes Obes Metab. 2020 Apr;22(4):640-647. doi: 10.1111/dom.13939. Epub 2019 Dec 22. PubMed 31808298 ↗
  • Tillner J, Posch MG, Wagner F, Teichert L, Hijazi Y, Einig C, Keil S, Haack T, Wagner M, Bossart M, Larsen PJ. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes Metab. 2019 Jan;21(1):120-128. doi: 10.1111/dom.13494. Epub 2018 Sep 16. PubMed 30091218 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2015
First posted
Apr 8, 2015
Start
Mar 2015
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Last update
Jun 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02411825
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 8, 2015
Start date
Mar 2015
Primary completion
Jan 2016
Completion
Jan 2016
Last update
Jun 15, 2018

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SAR425899 · Metformin

Start the discussion